Safety Extension Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis

Inclusion Criteria: * Completer of the IMPALA trial. * Females who have been post menopausal for \>1 year, or females of child-bearing potential who are not pregnant or lactating and are using acceptable contraceptive methods. * Males agreeing to use using acceptable contraceptive methods. * Willing and able to provide signed informed consent. Exclusion Criteria: * Treatment with GM-CSF products other than molgramostim nebuliser solution within three months of Baseline. * Treatment with any investigational medicinal product other than inhaled molgramostim within four weeks of Baseline. * History of allergic reactions to GM-CSF. * Connective tissue disease, inflammatory bowel disease or other autoimmune disorder requiring treatment associated with significant immunosuppression, e.g. more than 10 mg/day systemic prednisolone. * Previous experience of severe and unexplained side effects during aerosol delivery of any kind of medicinal product. * History of, or present, myeloproliferative disease or leukaemia. * Apparent pre-existing concurrent pulmonary fibrosis. * Any other serious medical condition which in the opinion of the investigator would make the subject unsuitable for the trial.